{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:22:39Z","timestamp":1773523359536,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"DOI":"10.7759\/cureus.98011","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:08:06Z","timestamp":1764338886000},"source":"Crossref","is-referenced-by-count":1,"title":["Linagliptin-Induced Bullous Pemphigoid: A Case Report and Comprehensive Literature Review"],"prefix":"10.7759","author":[{"given":"Saood","family":"Almutairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falah M","family":"Alajmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman M","family":"Albthali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehab","family":"Aldhafiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2012.04.004","article-title":"Linear IgA disease: clinical presentation, diagnosis, and pathogenesis","volume":"32","author":"Venning VA","year":"2012","unstructured":"Venning VA. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Immunol Allergy Clin North Am. 2012, 32:245-53. 10.1016\/j.iac.2012.04.004","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly P","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, et al.. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002, 346:321-7. 10.1056\/NEJMoa011592","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani C","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, et al.. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015, 172:867-77. 10.1111\/bjd.13717","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194376","article-title":"First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in Asian populations: systematic review and network meta-analysis","volume":"10","author":"Wu KL","year":"2021","unstructured":"Wu KL, Chen HL, Tsai YM, et al.. First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in Asian populations: systematic review and network meta-analysis. J Clin Med. 2021, 10:4376. 10.3390\/jcm10194376","journal-title":"J Clin Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen M","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018, 78:1090-6. 10.1016\/j.jaad.2017.12.038","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat R","year":"2020","unstructured":"Abdat R, Waldman RA, de Bedout V, et al.. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020, 83:46-52. 10.1016\/j.jaad.2020.01.089","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2939","article-title":"Bullous pemphigoid associated with linagliptin treatment","volume":"152","author":"Haber R","year":"2016","unstructured":"Haber R, Fayad AM, Stephan F, Obeid G, Tomb R. Bullous pemphigoid associated with linagliptin treatment. JAMA Dermatol. 2016, 152:224-6. 10.1001\/jamadermatol.2015.2939","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley JA","year":"2009","unstructured":"Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009, 123:704-5. 10.1016\/j.jaci.2008.11.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2011.606452","article-title":"Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update","volume":"45","author":"Czernik A","year":"2012","unstructured":"Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012, 45:111-8. 10.3109\/08916934.2011.606452","journal-title":"Autoimmunity"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12890\/2019_001207","article-title":"Linagliptin-associated alopecia and bullous pemphigoid","volume":"6","author":"Someili A","year":"2019","unstructured":"Someili A, Azzam K, Hilal MA. Linagliptin-associated alopecia and bullous pemphigoid. Eur J Case Rep Intern Med. 2019, 6:001207. 10.12890\/2019_001207","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen K","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019, 10:1238.","journal-title":"Front Immunol"},{"key":"ref12","article-title":"Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid","volume":"34","author":"Ben Mordehai Y","year":"2019","unstructured":"Ben Mordehai Y, Faibish H, Astman N, Greenberger S, Barzilai A, Baum S. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid. J Eur Acad Dermatol Venereol. 2019, 34:161-5.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.det.2011.03.010","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"29","author":"Schmidt E","year":"2011","unstructured":"Schmidt E, Della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 2011, 29:427-38.","journal-title":"Dermatol Clin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430476-linagliptin-induced-bullous-pemphigoid-a-case-report-and-comprehensive-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:08:07Z","timestamp":1764338887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430476-linagliptin-induced-bullous-pemphigoid-a-case-report-and-comprehensive-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.98011","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}